Downregulation of serum IGF-1 for treatment of early worsening of diabetic retinopathy: A long-term follow-up of two cases

Ophthalmologica

Volumn 224, Issue 4, 2010, Pages 243-246

  Chantelau, Ernst ^a   Meyer Schwickerath, Rolf ^c   Klabe, Karsten ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MARIEN HOSPITAL DÜSSELDORF   (Germany)

^c Practice of Ophthalmology   (Germany)

Author keywords

Diabetic retinopathy; Growth factors; Insulin therapy

Indexed keywords

HEMOGLOBIN A1C; INSULIN; SILICONE OIL; SOMATOMEDIN; SOMATOMEDIN 1; TRIAMCINOLONE; UNCLASSIFIED DRUG; SOMATOMEDIN C;

ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CATARACT; DIABETIC RETINOPATHY; DOWN REGULATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RETINA NEOVASCULARIZATION; SECONDARY GLAUCOMA; VISUAL ACUITY; VITRECTOMY; BLOOD; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; DIABETIC RETINOPATHY; DOWN-REGULATION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VISUAL ACUITY;

EID: 70450159843     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000260231     Document Type: Article

References (13)

1. Chantelau E: Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998; 82: 725-730.
2. Gomez-Peralta F, Pujante P, Abreu C, Santos E, Garcia-Layana A, Salinas A, Varo N: Retinal thickness after insulin therapy initiation in patients with type 2 diabetes. An optical coherence tomography (OCT) based study (abstract). Diabetologia 2007; 50(suppl 1): S448.
3. Chantelau E, Frystyk J: Progression of diabetic retinopathy during improved metabolic control may be treated with reduced insulin dosage and/or somatostatin analogue administration - a case report. Growth Horm IGF Res 2005; 15: 130-135.
4. Chantelau E, Meyer-Schwickerath R: Reversion of 'early worsening' of diabetic retinopathy by deliberate restoration of poor metabolic control. Ophthalmologica 2003; 217: 373-377.
5. Suto C, Hori S, Kato S, Muraoka K, Kitano S: Effect of perioperative glycemic control in progression of diabetic retinopathy and maculopathy. Arch Ophthalmol 2006; 124: 38-45.
6. Varughese G, Rao P, Barton D, Warner D: Changes in diabetic retinopathy noticed after chemotherapy for duodenal carcinoma. Br J Diabetes Vasc Dis 2004; 4: 206-208.
7. Chantelau E, Kimmerle R, Meyer-Schwickerath R: Insulin, insulin analogues and diabetic retinopathy. Arch Physiol Biochem 2008; 114: 54-62.
8. Simo R, Hernandez C: Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008; 51: 1574-1580.
9. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, Nishida K: Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008; 145: 854-861.
10. Jonas JB: Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol 2007; 39: 96-110.
11. The Diabetes Control and Complications Trial Research Group: Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116: 874-886; Erratum: Arch Ophthalmol 1998; 116: 1469.
12. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN, for the DCCT/EDIC Research Group: Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial - revisited. Diabetes 2008; 57: 995-1001.
13. Arar NH, Freedman BI, Adler SG, et al.: Heritability of the severity of diabetic retinopathy: the FIND-Eye Study. Invest Ophthalmol Vis Sci 2008; 49: 3839-3845.